Compare Novo Nordisk A/S (NVO) vs Palo Alto Networks Inc (PANW) Price & Performance

Novo Nordisk A/STrade

Palo Alto Networks IncTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Palo Alto Networks Inc — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Palo Alto Networks Inc trades at $341.22 (market cap $284.16B). The key difference: Palo Alto Networks Inc is the larger of the two by market cap, and Novo Nordisk A/S pays a 3.63% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals.

	NVO	PANW
Market Cap	$220.53B	$284.16B
Sector	Health	Technology
52-Week High	$71.70	$358.68
52-Week Low	$35.29	$141.67
Enterprise Value	$239.49B	$283.12B
Dividend Yield	3.63%	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVO

Novo Nordisk sues Eli Lilly over misleading GLP-1 drug ads claiming superior weight-loss results.Proactive Investors · 11 hours agoBearish Novo Nordisk sues Eli Lilly over misleading ads on obesity and diabetes drug efficacy.CNBC · 15 hours agoBearish Novo Nordisk shares jump 27% on strong sales of oral Wegovy and market expansion.Seeking Alpha · 1 day agoBullish View details →

PANW

Palo Alto Networks to acquire Embrace, adding Real User Monitoring and Synthetics to boost app performance insights.PRNewsWire · 6 hours agoBullish Argus Research raises Palo Alto Networks price target to $425 on booming AI-driven cybersecurity demand.Danny Green · 8 hours agoBullish Cybersecurity ETFs soar as investors shift from semiconductors amid rising cyber threats and AI risks.ETF Trends · 9 hours agoBullish View details →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About Palo Alto Networks Inc

Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.